Navigation Links
PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/13/2011

ANNAPOLIS, Md., Jan. 13, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company recently presented new data from its anthrax anti-toxin and recombinant Protective Antigen (rPA) anthrax vaccine programs at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop and the Biomedical Advanced Research and Development Authority (BARDA) Industry Day, held January 11 – 13, 2011 in Washington, DC.

"BARDA continues to move forward to work closely with industry in the development and procurement of new medical countermeasures," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer of PharmAthene.  "We are delighted to present new data from our biodefense programs, which demonstrate progress towards our shared goal of enhancing biodefense national security initiatives.  As the data illustrate, PharmAthene continues to advance its pipeline and further its leadership position in biodefense."

Valortim® Anthrax Anti-Toxin Findings Reported

In an oral presentation entitled, "Comparison of Functional Activity and Pharmacokinetic Data from Nonclinical Valortim® Efficacy Studies: Implications for the Animal Rule" Dr. James Bourdage, Director of Bioanalytical Assay Development, at PharmAthene presented a biostatistical analysis of pharmacokinetic and toxin neutralization assay results for multiple Valortim® doses in three separate animal species – the African Green Monkey, New Zealand White Rabbit and Cynomolgus Monkey.

In these studies, animals were exposed to anthrax spores and subsequently treated with various doses of Valortim® upon detection of antigenemia (evidence of bacterial infection in the blo
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmAthene to Host Third Quarter 2010 Conference Call and Webcast on Thursday, November 11, 2010
2. PharmAthene Announces Closing of $15 Million Public Offering
3. PharmAthene Appoints Eric I. Richman President and Chief Executive Officer
4. PharmAthene Provides Update on NYSE Amex Listing Compliance Plan
5. PharmAthene Completes Previously Announced Registered Direct Offering
6. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
7. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
8. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
9. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
10. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
11. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
(Date:7/25/2014)... HILL, N.C. , July 25, 2014  Corporate ... challenges, including understanding new advancements in technology and how ... of this, libraries in the pharmaceutical and medical device ... value of the information and services they provide. ... Best Practices, LLC there are many forces of change ...
(Date:7/25/2014)... 2014  Smile Train and its technology partner BioDigital ... Surgery Simulator among leading global health innovations in The ... Washington, D.C. at The John ... "Smile Train is honored to be represented through ... innovators in health and medicine that TEDMED unites each ...
Breaking Medicine Technology:QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Forces of Change Reshaping Corporate Libraries & Information Services 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3
... , ATLANTA, Dec. 23 MiMedx Group, Inc. ... launched its first product, Paradis Vaso Shield(TM). In April ... for use as a cover for vessels following anterior vertebral ... hydrogel product protected by multiple patents and patent applications, as ...
... FRANCISCO, Dec. 23 Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing ... that management will present at the following upcoming investor conferences. , ... January 12, 2010, 9:40 a.m. PT, ... OneMedForum 2010, Wednesday, January 13, 2010, ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3
(Date:7/28/2014)... Sarasota-based FCCI Insurance Group (FCCI) was ... For. Still headquartered in Sarasota where it was originally ... in the top ten of the Best Large Companies ... the August issue of Florida Trend magazine. One-hundred companies ... Ranked #7 for 2014, FCCI has been in the ...
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... 28, 2014 The Wireline Services Market in ... Europe with analysis and forecast of revenue. The Wireline services ... billion in 2013 to $2.4 billion by 2019, at a ... the TOC of the Wireline Services Market in Europe report, ... also provides a glimpse of the segmentation in the European ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- People with ... for obesity and diabetes, a new study suggests. ... that brown fat actually improves insulin sensitivity, blood sugar ... for overweight and obese people," Labros Sidossis, a professor ... at the University of Texas Medical Branch at Galveston, ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2
... Colonic lipomas have been found in related literature. One ... 14 issue of the World Journal of Gastroenterology because ... discussed age and sex factors, clinical and histopathological findings, ... and previously available literature. , The article reported ...
... Food and Drug Administration (FDA) has awarded the ... $1 million Orphan Products Development grant to study ... skin or internal organs., The unique, interdisciplinary, and ... Drolet, M.D., professor of dermatology and pediatrics, at ...
... Researchers at the Board of Governors Gene Therapeutics Research ... first time that it is possible to sustain therapeutic ... to a year, even in the presence of an ... humans. , The researchers demonstrated in an animal ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... long-term outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... peptide (ANP) can lessen cardiac injuries after heart attack and ... a Japanese study in this week,s issue of The ... damaged heart muscle (infarct) and lessened what,s known as "reperfusion ...
... 26 AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Inc Webcast, When: November 1, 2007 @ 8:30 AM ... over the Internet -- Simply log on to the web at ... Contact: Lisa Gould of AMICAS, Inc, 617-779-7892. If you ...
Cached Medicine News:Health News:The largest colonic lipoma to date 2Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2
...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: